CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Some of the directors and officers of the Company are at present, as in the past, customers of the Company, and the Company has had, and expects to have in the future, banking relationships in the ordinary course of its business with directors, officers, principal shareholders, and their associates, on substantially the same terms, including interest rates and collateral on loans, as those prevailing at the same time for comparable transactions with persons not related to the Company. These transactions do not involve more than the normal risk of collectability or present other unfavorable features.
The Company has not adopted a formal policy that covers the review and approval of related person transactions by the Board. The Board, however, does review all such transactions that are proposed to it for approval. During such a review, the Board will consider, among other things, the related person’s relationship to the Company, the facts and circumstances of the proposed transaction, the aggregate dollar amount of the transaction, the related person’s relationship to the transaction, and any other material information. The Company’s Governance Committee also has the responsibility to review significant conflicts of interest involving directors or executive officers.
Private Placements
On April 3, 2024 and June 13, 2024, the Company closed private placements in which it issued and sold shares of its common and preferred stock for gross proceeds of $150.0 million and $11.6 million, respectively (collectively, the “Private Placements”). At a special meeting of shareholders held on June 20, 2024, the Company’s shareholders approved the conversion of the preferred shares issued in the Private Placements into shares of the Company’s common stock. On June 28, 2024, all outstanding shares of the Company’s Mandatorily Convertible Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”) were automatically converted into 50,232,000 shares of the Company’s common stock. On November 7, 2024, the Company issued 10,928,000 shares of its common stock to Castle Creek Capital Partners VIII, LP, a Delaware limited partnership (“Castle Creek”), the sole shareholder of the Company’s Mandatorily Convertible Cumulative Perpetual Preferred Stock, Series C (the “Series C Preferred Stock”), in exchange for the 2,732 shares of Series C Preferred Stock held by Castle Creek. The Private Placements also included the issuance of warrants to purchase 6,549 shares of Series B Preferred Stock and 1,411 shares of Series C Preferred Stock. On June 28, 2024, the warrants for the Series B Preferred Stock were automatically converted into warrants to purchase 26,196,000 shares of common stock (subject to certain beneficial ownership limitations). On November 7, 2024, the Company issued a warrant exercisable into 5,764,000 shares of common stock in exchange for the warrant exercisable into 1,441 shares of Series C Preferred Stock held by Castle Creek, the sole warrant issued by the Company relating to the Series C Preferred Stock.
On April 3, 2024, in connection with the Private Placements, the Company issued and sold 1,186,157 shares of common stock, 4,703 shares of Series B Preferred Stock, and warrants to purchase 2,500 shares of Series B Preferred Stock at an exercise price of $10,000.00 per share, to Kenneth R. Lehman for a purchase price of approximately $50.0 million.
On April 3, 2024, in connection with the Private Placements, the Company issued and sold 593,078 shares of common stock, 2,732 shares of Series C Preferred Stock, and warrants to purchase 1,411 shares of Series C Preferred Stock at an exercise price of $10,000.00 per share, to Castle Creek for a purchase price of approximately $28.8 million.
On April 3, 2024, in connection with the Private Placements, the Company issued and sold (i) 14,284.76 shares of common stock, approximately 56.84 shares of Series B Preferred Stock and a warrant to purchase approximately 30.35 shares of Series B Preferred Stock, at an exercise price of $10,000.00 per share, to Trevor Montano, a director of the Company, for a purchase price of approximately $0.6 million, (ii) 9,457.99 shares of common stock, approximately 37.64 shares of Series B Preferred Stock and a warrant to purchase approximately 20.09 shares of Series B Preferred Stock, at an exercise price of $10,000.00 per share, to James Montano, the father of Trevor Montano, for a purchase price of $0.4 million and (iii) 5,911.25 shares of common stock, approximately 23.52 shares of Series B Preferred Stock and a warrant to purchase approximately 12.56 shares of Series B Preferred Stock, at an exercise price of $10,000.00 per share, to an investor, for whom Trevor Montano managed such investor’s account, for a purchase price of $0.25 million.
On April 3, 2024, in connection with the Private Placements, the Company issued and sold to the following individuals the stated number of shares of Series B Preferred Stock at a price of $10,000.00 per share: 100 shares to Mr. Beale, President and Chief Executive Officer and a director of the Company, for a purchase price of $1.0 million; 25 shares to Mr. Bost, a director of the Company, for a purchase price of $250,000; 25 shares to Mensel D. Dean, Jr., then a director of the Company, for a purchase price of $250,000; 25 shares to Ms. Gavant, Executive Vice President and Chief Financial Officer of the Company, for a purchase price of $250,000; 25 shares to Mr. Spilman, a director of the Company, for a purchase price of $250,000; 20 shares to Mr. Stokes, a director of the Company, for a purchase price of $200,000; and 15 shares to Ms. Woodruff, a director of the Company, for a purchase price of $150,000.
25